IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

33.72 -0.54 (-1.58%)

Delayed Quote Updated: 12:19 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial ↗

September 12, 2022

Via Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗

September 12, 2022

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Via Benzinga

Why IDEAYA Biosciences Shares Plunging Today ↗

August 15, 2022

Via Benzinga

Recap: IDEAYA Biosciences Q1 Earnings ↗

May 10, 2022

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises ↗

September 12, 2022

Pre-open movers

Via Benzinga

Oracle, JPMorgan And 3 Stocks To Watch Heading Into Monday ↗

September 12, 2022

With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Looking Into IDEAYA Biosciences's Return On Capital Employed ↗

September 09, 2022

Benzinga Pro data, IDEAYA Biosciences (NASDAQ:IDYA) reported Q2 sales of $5.85 million. Earnings fell to a loss of $22.06 million, resulting in a 57.4% decrease from last quarter.

Via Benzinga

IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia ↗

September 06, 2022

IDEAYA Biosciences (NASDAQ: IDYA) has initiated Investigator Sponsored Trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM)...

Via Benzinga

IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate ↗

August 29, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 29, 2022

Via Benzinga

AppLovin, Unity Software And Some Other Big Losers From Monday ↗

August 16, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining around 150 points. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday ↗

August 16, 2022

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.

Via Benzinga

Gold Drops Over 1%; Viridian Therapeutics Shares Spike Higher ↗

August 15, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones around 170 points on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 15, 2022

Via Benzinga

Stocks Trim Morning Losses Ahead Of Retail Earnings ↗

August 15, 2022

Investors are eyeing an influx of earnings from the retail sector later in the week.

Via Talk Markets

Dow Surges Over 100 Points; Crude Oil Falls Sharply ↗

August 15, 2022

U.S. stocks traded turned higher midway through trading, with the Dow Jones gaining more than 100 points on Monday.

Via Benzinga

U.S. Stocks Edge Lower; NY Empire State Manufacturing Index Drops In August ↗

August 15, 2022

U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday.

Via Benzinga

Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session ↗

August 15, 2022

Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New...

Via Benzinga

Recap: IDEAYA Biosciences Q2 Earnings ↗

August 15, 2022

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q2 earnings results on Monday, August 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings IDEAYA Biosciences missed...

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

IDEAYA's Cancer Candidate Shows Early Tumor Modulation ↗

July 27, 2022

Via Benzinga

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK ↗

June 28, 2022

Via Benzinga

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma ↗

May 02, 2022

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 15, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 16, 2022

On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial ↗

March 15, 2022

IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: IDEAYA Biosciences Q4 Earnings ↗

March 15, 2022

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For March 15, 2022 ↗

March 15, 2022

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.